{"Clinical Trial ID": "NCT00127933", "Intervention": ["INTERVENTION 1:", "HER2-Neu Negative", "Dose and route per treatment cycle (Q3W):", "Capecitabine: 825 mg/m2, oral, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1", "HER2-neu negative: capecitabine + docetaxel", "Duration: Four 3-week treatment cycles", "INTERVENTION 2:", "HER2-Neu Positive", "Dose and route per treatment cycle (Q3W):", "1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, IV infusion 90 min; thereafter 2 mg/kg, IV infusion 30 min, per week", "HER2-Neu positive: capecitabine + docetaxel + trastuzumab", "Duration: Four 3-week treatment cycles"], "Eligibility": ["Incorporation criteria:", "Women >=18 years of age;", "A new diagnosis;", "Infiltrating breast cancer (invasive) HER2-neu-negative or HER2-neu-positive.", "- Exclusion criteria:", "Signs of metastatic disease, with the exception of ipsilateral axillary lymph nodes (same side);", "Previous systemic or local primary treatment."], "Results": ["Performance measures:", "Percentage of participants assessed for a more complete complete pathological response (CPR) in primary breast tumours at the time of definitive surgery", "The complete pathological response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue sample removed from the breast after 4 cycles of preoperative treatment. Near pCR (npCR) was defined as the presence of invasive tumour cells of a size of 5 mm or less in the tissue sample removed from the breast after 4 cycles of preoperative treatment. Only pathological assessments occurring prior to the first date of adjuvant treatment were included in the analysis of pCR.", "Duration: at the time of definitive surgery; after four cycles of 3 weeks (3-4 months)", "Results 1:", "Title of arm/group: HER2-Neu Negative", "Description of the arm/group: Dose and route per treatment cycle (Q3W):", "Capecitabine: 825 mg/m2, oral, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1", "HER2-neu negative: capecitabine + docetaxel", "Duration: Four 3-week treatment cycles", "Total number of participants analysed: 101", "Type of measurement: Number", "Unit of measure: percentage of participants 15.8 (9.7-25.4)", "Results 2:", "Title of arm/group: HER2-Neu Positive", "Description of the arm/group: Dose and route per treatment cycle (Q3W):", "1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, IV infusion 90 min; thereafter 2 mg/kg, IV infusion 30 min, per week", "HER2-Neu positive: capecitabine + docetaxel + trastuzumab", "Duration: Four 3-week treatment cycles", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measure: percentage of participants 50.0 (31.9-71.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/122 (12.30 per cent)", "- febrile neutropenia 4/122 (3.28%)", "Neutropenia 0/122 (0.00 %)", "Unstable Angina 1/122 (0.82%)", "Coronary artery disorders 1/122 (0.82%)", "Myocardial infarction 1/122 (0.82%)", "Diarrhoea 2/122 (1.64%)", "- Collision 1/122 (0.82%)", "Pyrexia 2/122 (1.64%)", "Chest pain 1/122 (0.82%)", "Pneumonia 1/122 (0.82%)", "- Cellulite from catheter site 1/122 (0.82%)", "Adverse Events 2:", "Total: 7/34 (20.59 per cent)", "Febrile neutropenia 1/34 (2.94 %)", "Neutropenia 1/34 (2.94%)", "Unstable Angina 0/34 (0.00 %)", "Coronary heart disease 0/34 (0.00 %)", "Myocardial infarction 0/34 (0.00 %)", "Diarrhoea 0/34 (0.00 %)", "- Collite 0/34 (0.00 per cent)", "Pyrexia 0/34 (0.00 %)", "- Thoracic pain 0/34 (0.00 %)", "Pneumonia 1/34 (2.94%)", "- Cellulite from catheter site 0/34 (0.00 %)", "Infection 1/34 (2.94 per cent)"]}